✦ LIBER ✦

Killing of Fas ligand-resistant renal carcinoma cells by interleukin-2- and BCG-activated effector cells

✍ Scribed by Sven Brandau; Henrik Suttmann; Hans-Dieter Flad; Dieter Jocham; Andreas Böhle

Book ID: 105968015
Publisher: Springer-Verlag
Year: 2000
Tongue: English
Weight: 169 KB
Volume: 49
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s002620000118

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Human tumor cell lines with pleiotropic

Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes

✍ P. Allavena; M. Grandi; M. D'Incalci; O. Geri; F. C. Giuliani; A. Mantovani 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 French ⚖ 371 KB

Two human cell lines, the colon carcinoma Lovo and the BME-supplemented medium with 10% FBS. 1mM glutamhe, transformed intestinal 1-407, and their variants (LOVO /Dx and 50 u/ml penicillin and 50 pg/ml streptomycin. I-407/Dx), with pleiotropic resistance to cancer chemotherapeutic drugs, were exami

Prostaglandin E2 inhibits T cell activat

Prostaglandin E2 inhibits T cell activation-induced apoptosis and Fas-mediated cellular cytotoxicity by blockade of Fas-ligand induction

✍ Brian O. Porter; Thomas R. Malek 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

Killing ofParacoccidioides brasiliensisy

Killing ofParacoccidioides brasiliensisyeast cells by IFN-γ and TNF-α activated murine peritoneal macrophages: evidence of H2O2and NO effector mechanisms

✍ Ana Paula Moreira; Luciane Alarcão Dias-Melicio; Maria Terezinha S. Peraçoli; Su 📂 Article 📅 2008 🏛 Springer Netherlands 🌐 English ⚖ 256 KB

Inhibition of Colony Formation of Drug-r

Inhibition of Colony Formation of Drug-resistant Human Tumor Cell Lines by Combinations of Interleukin-2-activated Killer Cells and Antitumor Drugs

✍ Ohtsu, Atsushi ;Sasaki, Yasutsuna ;Tamura, Tomohide ;Fujiwara, Yasuhiro ;Ohe, Yu 📂 Article 📅 1989 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 350 KB

A phase II trial of interleukin-2 by con

A phase II trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma

✍ A. Mittelman; C. Puccio; T. Ahmed; J. Zeffren; A. Choudhury; Z. Arlin 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 374 KB 👁 2 views

Phase iii randomized trial of interleuki

Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

✍ Teresa Murray Law; Robert J. Motzer; Madhu Mazumdar; Kenneth W. Sell; Philip Wal 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 723 KB

Background. Treatment with interleukin-2 (IL-2) and lymphokine-activated killer cells (LAK) resulted in responses in some patients with advanced renal cell carcinoma (RCC). However, the relative therapeutic benefit of the addition of LAK to IL-2 was unknown. Methods. A randomized Phase I11 trial wa